Novartis Simulect Plus Triple Therapy Shows 21% Transplant Rejection Rate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adding Novartis’ monoclonal antibody therapy Simulect to a triple immunosuppressive regimen for prophylaxis of renal transplant rejection resulted in a 21% rate of acute rejection in the first six months following transplant compared to a 35% rate for placebo plus triple therapy, labeling states.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class